Biosciences, a leading provider of premium vector technology and services for the production of biologics, is announcing the launch of its LV-2G UNic Early Access Programme.
LV-2G UNic marks a significant milestone in lentivirus manufacturing optimisation, offering access to groundbreaking vector technology designed to revolutionise viral vector production.
Participants can achieve significant enhancements in titers, paving the way for increased viral vector production capacity and substantial improvements in manufacturing cost efficiency.
Frank Pieper, CEO of ProteoNic, sharing his excitement about the program's potential impact, stated: "The LV-2G UNic Early Access Program will serve as a launching platform for our viral vector manufacturing innovation. By offering early access to our state-of-the-art vector technology, we empower researchers to unlock unprecedented levels of efficiency and productivity in viral vector manufacturing."
LV-2G UNic represents next generation vector technology, engineered to elevate lentiviral titers across a wide array of expression systems.
The technology drives enhanced infectious viral particle production, by providing a significant boost in gRNA production through increased transcription levels achieved with ProteoNic’s patented Dual Promoter system.
Participation in the LV-2G UNic Early Access Programme offers exclusive benefits, including access to ProteoNic’s cutting-edge LV-2G UNic vector technology, optimising lentiviral particle expression and co-development opportunities.
This technology can be seamlessly integrated into current workflows with minimal to no process development required.
